Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A, C, W135 and Y conjugate vaccine (Pfizer)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Nimenrix is a quadrivalent meningococcal conjugate vaccine (MenACWY) indicated for active immunization against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W-135, and Y. The vaccine is composed of the capsular polysaccharides of these four serogroups, each individually conjugated to a tetanus toxoid (TT) carrier protein. This conjugation converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, which enhances immunogenicity, induces higher antibody titers, and establishes immunological memory, particularly in infants and young children. Nimenrix is typically administered as a single intramuscular injection and is approved for use in individuals starting from 6 weeks of age. Originally developed by GSK, the product was acquired by Pfizer in 2015 and is frequently used as a licensed comparator in clinical trials for next-generation meningococcal vaccines.
- Brand names
- Nimenrix
- Other names
- MenACWY-TTQuadrivalent meningococcal conjugate vaccinemeningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal group A, C, W135 and Y conjugate vaccine (Pfizer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A, C, W135 and Y conjugate vaccine (Pfizer).